In order to assess the potential clinical benefit of filgrastim (G-CSF) after peripheral blood stem cell (PBSC) autotransplantation a randomized study was begun in our center in July 1997: 62 patients were involved (30 received filgrastim after PBSC infusion and 32, the control group, received no cytokines). All were adults (median 40 years, range 18-65). Patients with one of three different pathologies were recruited: 28 had advanced breast carcinoma, 23 had lymphomas (12 Hodgkin's disease and 11 non-Hodgkin's lymphoma) and 11 had de novo AML. All of them were transplanted using myeloablative chemotherapy conditioning regimens. G-CSF was administered subcutaneously from day +5 in the treated group at a dose of 5 g/kg body weight/day. The numbers of CD34 + and mononuclear (MNC) cells infused were similar in each group. Only minor differences regarding the use of G-CSF could be inferred from the analysis of the data. Faster granulocyte engraftment was evident in the treated group (mean of 10 vs 12 days to achieve Ͼ0.5 × 10 9 /l granulocytes, P = 0.0008), without differences in incidence and severity of infections, days of fever or duration of antibiotic treatment between groups. There was slightly slower platelet engraftment (mean of 15 days in the group with G-CSF vs 12 days in the other group to achieve Ͼ20 × 10 9 /l platelets, P = NS) in this series, but there were no differences in incidence and severity of haemorrhage or platelet transfusion support. Considering the economical costs, the median expenditure per inpatient stay was Eur5961 (range Eur4386-Eur17186) in the G-CSF group compared with Eur5751 (range Eur3676-Eur15640) in the control group (P = 0.47). From our data it could be concluded that for adult patients transplanted with PBSC there is no clear beneficial impact of post-infusion G-CSF administration.
Despite the large number of PBSC autotransplants performed nowadays and the ample experience using recombinant cytokines in this particular setting, very few published randomized studies explore the real clinical impact of the use of filgrastim (G-CSF) in PBSC autotransplantation. Only five recent reports have analyzed in a prospective manner the possible benefit of the administration of G-CSF after PBSC autotransplantation since 1997 (one of them used the glycosylated form, lenograstim). [1] [2] [3] [4] [5] In four of these studies the authors recommended the use of G-CSF on the basis of the favourable clinical results. A recent Japanese study performed in children has questioned this support for the use of G-CSF and reported a limited clinical benefit from this cytokine in PBSC autotransplantation. 5 This article summarizes our clinical experience using G-CSF (filgrastim) after PBSC transplantation in adults, reporting the results of a prospective and randomized trial performed in our hospital in the past months.
Materials and methods

Patients
Between July 1997 and November 1998, 62 patients were referred to our service and recruited for the study. The patients had different neoplastic diseases: 28 with breast carcinoma in advanced stages, 12 with Hodgkin's disease (HD), 11 with non-Hodgkin lymphomas (NHL) and 11 with de novo AML who were autotransplanted using PBSC. Clinical data at the time of transplantation and the characteristics of both treatment groups (with and without G-CSF) are given in Table 1 . There were no statistical differences for age, sex, diagnosis, remission status, interval between diagnosis and autotransplantation, number of mononuclear and CD34
+ cells infused by body weight, platelet count before transplantation or conditioning employed between the different groups. The control group had more irradiated patients. The time period analyzed in this study ran from PBSC infusion to discharge. The median follow-up after transplantation was 9 months (range 3.5-19) for the whole series. Multiple variables in the patients' post-transplantation evolution were recorded and analyzed in order to reveal any possible difference between the groups. PBSC were collected from patients after intensive chemo-and/or radiotherapy. Harvest was scheduled at least 1 month after 602 the last chemotherapy session. PBSC were mobilized using rhG-CSF (filgrastim ICD; Amgen, F Hoffman-La Roche, Basel, Switzerland); 10 g/kg/day were administered s.c. on the 4 days prior to harvest and for the duration of the procedure. Harvesting was scheduled to terminate when the total number of CD34 + cells obtained reached 2.5 × 10 6 /kg body weight. This threshold was achieved in most of the patients. The procedures for harvesting and cryopreservation were as previously described. 6 All patients gave informed written consent. Each patient was randomly allocated to one of the study groups at the beginning of the transplantation procedure prior to conditioning.
An estimate of the stem cell number in the inoculate was determined by analysis of the CD34 + mononuclear cells, employing a direct immunofluorescence flow cytometry assay. Cells were thawed by rapid heating of the cryopreservation bags through immersion in a 40°C water bath. The bags were thawed one by one, and a new bag was not thawed until the last bag had been completely infused. Before infusion, 3 ml of the thawed solution was obtained for viability, cytologic and microbiological control tests. Viability was assessed by trypan blue exclusion. Immediately after thawing, the PBPC were rapidly infused via a Hickman's central line.
Conditioning regimens
Patients received different marrow-ablative regimens, depending on their diagnoses. The patients diagnosed as having AML received busulfan and cyclophosphamide as conditioning. 8 Carboplatin, cyclophosphamide and thiotepa were used in women with breast carcinoma. 9 The BEAC regimen was followed in the lymphoma cases. 10 The lowest numbers for peripheral blood counts after conditioning ranged between 0 and 0.7 × 10 9 /l (median 0.1) for leucocytes and 2 to 27 × 10 9 /l (median 11) for platelets. No differences were observed between the two study groups.
Clinical management and support measures
Before myeloablative therapy, the patients were nursed in single rooms using simple reverse isolation measures. PBSC were reinfused after thawing on day 0 (considering as day 0 the first day of PBSC infusion). RBC concentrates were transfused when the hemoglobin value was less than 9 g/dl and random platelet transfusions were employed when platelet count was less than 15 × 10 9 /l or bleeding had occurred.
Total parenteral nutrition (TPN) was initiated on day +2 in all patients and discontinued when oral nutrition was resumed. All patients received the same prophylactic antibiotherapy, consisting of acyclovir, fluconazol and cotrimoxazol. Intravenous broad-spectrum antibiotic treament was initiated when the axillary temperature was higher than 38.5°C with a third-generation cephalosporin, amikacin and vancomicin. Amphotericin B (liposome complex, Abelcet; Esteve Hospital, Barcelona, Spain) was added after 3 days of persistent fever.
In the treated group, filgrastim (5 g/kg body weight) (Amgen, F Hoffman-La Roche), administered daily as a single s.c. injection, was initiated on day +5, and continued until the absolute neutrophil count was higher than 1.5 × 10 9 /l. The day of initiation was decided after a previous randomized study in our centre demonstrated that the results of delayed administration were similar to those of early filgrastim administration (reported by others). 11, 12 The control group received no colony-stimulating factors.
Discharge occurred when the patient was engrafted, free of fever, independent of RBC transfusion or any other eventual complication (complete platelet engraftment was not necessary for discharge). The decision was jointly agreed upon by the three physicians (always the same) responsible for the clinical unit.
Cost analysis
Costs for filgrastim (if appropriate), i.v. antibiotics, platelet and red cell concentrates, parenteral nutrition and occupiedbed days from day 0 were totalled for each patient. Prophylactic antibiotics were not included. The calculated unit cost of an occupied-bed day in our transplantation unit for the year 1998 was Eur232.60 and includes personal expenses, laboratory, radiologic and other special tests. The total cost for each patient was found by summing the number of resources consumed multiplied by their respective unit prices. Only transplantation in-patient time (from day 0 to discharge) was considered. Incidentals after the first discharge were not considered. Charges for conditioning chemotherapy, cell mobilization and harvest and cryopreservation were not considered in this analysis.
Statistical analysis
All data were collected using a custom-adapted File-Maker Pro (Macintosh, Apple Computer, Cupertino, CA, USA) database and analysed with Stat-View SE + Graphics software (Macintosh, Apple Computer). The differences between the medians for different variables were analyzed using the Mann-Whitney U test (quantitative variables) or chi-square test (qualitative variables). Actuarial survival curves were constructed according to the method of Kaplan and Meier. Survival was calculated from the date of day 0 to the date of death from any cause or end of the study period (February 1999).
Results
Engraftment kinetics and haematopoietic recovery
Data on engraftment kinetics and haematopoietic recovery are shown in Table 2 .
Granulocyte recovery over 0.5 × 10 9 /l was faster for the One patient died before day +100 and two others did not achieve complete engraftment. One patient died before day +100, one underwent myelodysplastic syndrome before day +100 (with a previous complete engraftment) and one did not achieve complete engraftment.
Table 3
Clinical outcome G-CSF group than for the control group (median 10 days, range 7-19, and median 12 days, range 9-20, respectively). The median lapse time in aplasia (days between less than 500 granulocytes and more than 500 granulocytes) was 9 days for the G-CSF-treated patients and 10 days for control patients. In the G-CSF group, the median time required for recovery of more than 20 × 10 9 /l platelets was 13 days (range 10-47), slightly slower than for the control group (median of 11 days, range 5-33). This difference was more evident but not significant with the number of patients available when the time to recover more than 50 × 10 9 /l platelets was considered (median of 18 days in G-CSF group and 14 in the controls).
The number of patients that received sub-optimal numbers of CD34 + cells (fixed at Ͻ2.5 × 10 6 /kg) was the same in the two groups: six patients in each group (P = 0.2). The engraftment kinetics for these patients with sub-optimal numbers of CD34 + cells was similar in both groups and to the patients with optimal numbers of CD34 + cells infused. Complete engraftment (defined as Ͼ1.5 × 10 9 /l granulocytes, Ͼ10 g/dl Hb and Ͼ50 × 10 9 /l platelets without stimulating factors or transfusional support) was evaluated on day +100 post-transplant and was achieved by the majority of patients in both groups. In the G-CSF-treated group, two patients did not engraft: a woman diagnosed with AML and transplanted in partial remission eventually relapsed and died 3 months after transplantation; the other, a man diagnosed with refractory HD, did not achieve erythrocyte or platelet engraftment and was diagnosed with secondary myelodysplastic syndrome; he died after an allogeneic PBSC transplantation 1 year after the first transplantation. In the control group without G-CSF, only one patient did not achieve a complete engraftment: a woman with AML transplanted at partial remission who has achieved no erythrocyte or platelet engraftment and is alive, but transfusion-dependent. In the same group, a woman with HD achieved complete engraftment, displayed progressive pancytopenia 2 months after transplantation and was diagnosed with secondary myelodysplastic syndrome.
Hospital course and toxicity after PBSC autograft
No patients died during the transplantation process and all left the hospital after the procedure. Two patients died before day +100 post-infusion, one in each group, although both had achieved complete engraftment: the first, in the G-CSF group, was a patient with refractory HD. He died of aspergillosis pneumonia 2 months after the PBSC infusion. The other, in the control group, died due to relapse of his NHL 3 months after day 0. At the time of analysis, six patients have died: four in the G-CSF group at 2, 3.4, 3.8 and 12.3 months after PBSC infusion (one from aspergillosis, two from relapse of their AML and the last one during a later allogeneic transplantation); and two in the control group from relapse of their disease at 3 and 11 months after infusion (with NHL and HD, respectively). No significant statistical differences in survival were observed between the two groups (median of 8.5 for the G-CSF group vs 10.3 months for the control group, P = 0.21).
No differences in terms of days with TPN, i.v. antibiotics, amphotericin B, or transfusional support were evident in our series between the two groups (Table 3 ). Days until discharge were similar between the two groups, without statistically relevant differences (mean of 18.6 Ϯ 1.6 (s.e.) days for the G-CSF group and 18.5 Ϯ 1 (s.e.) days for the control group, P = 0.46).
Because of the possible impact of the use of G-CSF on the incidence and severity of mucositis, the relevance of this complication was investigated in our patients by means of the WHO scale for mucositis 13 and the consumption of i.v. morphine (directly related to the duration of the most severe forms of mucositis) was recorded. No relevant differences in incidence, severity nor morphine consumption were evident in our series (Tables 3 and 4) .
Infectious and haemorrhagic complications
In order to evaluate the incidence and severity of infectious complications in our series, an original grading score system was used (Table 5 ). It showed no significant differences between the two study groups. Only a few patients in either group experienced severe or life-threatening infections (grades 3 and 4, 10% and 12% of patients, respectively). In all cases the infections resolved without sequelae. The treatment with G-CSF did not imply a lower consumption of i.v. antibiotics and/or amphotericin or fewer febrile days for these patients (Table 3) . Severe haemorrhagic complications appeared in eight patients: in the G-CSF group one patient experienced an autolimited haematuria due to prostatitis, one had a severe epistaxis and a third displayed oral mucosal and bilateral conjunctive haemorhage. In the control group, two patients experienced menorrhagia, one had cutaneous purpura, a fourth displayed severe epistaxis and a fifth (without platelet engraftment) experienced long-lasting haemorrhagic cystitis that ultimately resolved. There were no differences between the two groups in the number of transfused platelet concentrates (Table 3) .
Cost analysis
Taking into account the costs in our institution of occupiedbed days from day 0, antimicrobials used, G-CSF usage, total parenteral nutrition and transfusional support, the median expenditure per inpatient stay was Eur5961 (range Eur4386-Eur17186) in the G-CSF group compared with Eur5751 (range Eur3676-Eur15640) in the control group (P = 0.47) ( Table 6 ). The two groups of patients had the same economical expenses for all the parameters investigated (excluding the G-CSF).
Discussion
The major benefit of using PBSC instead of bone marrow for autotransplantation, in addition to the advantage of a 605 Table 6 Cost analysis simpler and less invasive method of obtaining progenitor cells, is the faster haematopoietic recovery. There is controversy as to whether the use of G-CSF after myeloablative conditioning also has a remarkably beneficial impact on PBSC autotransplantation. A few recent studies have explored this aspect in a prospective and randomized manner ( Table 7) . First of all it should be noted that extracting relevant and exactly comparable information from these different studies is difficult because of the many design variables. Diagnosis, age of patients (children in the study of Kawano et al 5 ), conditioning and state of remission at transplantation vary considerably in all these reports. Moreover, the type of G-CSF and schedule of treatment are also diverse: Linch et al 2 used a glycosylated form of G-CSF in their study and McQuaker et al 4 employed a low dose of G-CSF. The time of initiating filgrastim therapy also varies from the same day as PBSC infusion to the day +5. Added difficulties in some multicentric studies are the many centres involved with a comparativly low number of patients enrolled in each one (as is the case for the studies of Linch et al and Kawano et al), thus decreasing the value of possible differences among some variables regarding the use of G-CSF; particularly the days of hospitalization and the cost analysis. Despite these problems, all these publications, and our study is not an exception, demonstrate that the addition of G-CSF significantly accelerates granulocyte recovery after PBSC rescue (Table 7) . Unfortunately, this finding does not imply any clear benefit for the use of G-CSF in terms of a lower incidence of infections, days of fever or antibiotic consumption. Three studies 1, 3, 4 showed that the administration of filgrastim to autotransplanted patients resulted in a decreased use of intravenous antibiotics or amphotericin. In our study, this aspect has been carefully examined and we cannot demonstrate a clear benefit for G-CSF on the incidence and severity of infections or antibiotic support. With regard to platelet engraftment, most of the studies observed no differences in days to recovery of more than 20 × 10 9 /l platelets or to being transfusion independent. Only the study of Kawano et al and our study note an unfavourable trend in platelet recovery when G-CSF is used after transplantation; this has also been noted in another retrospective study on allogeneic transplantation.
14 This effect is more evident in our series when the days until reaching more than 50 × 10 9 /l platelets is analysed, and almost, reaches statistical significance (P = 0.069). Nevertheless, and this is the most relevant finding, this delay was not reflected in increased platelet transfusional support or increased haemorrhagic complications in the G-CSF-treated group. In our series we cannot demonstrate a beneficial impact from the use of G-CSF on hospitalization time (mean of 18 days in each group). Analysing the other reports, only three of them show that the use of G-CSF seems to shorten hospitalization (Table 7) . Nevertheless, these data are misleading in the study of Linch et al, in which the number of centres involved and the nonexistence of common criteria for patient discharge, diminish the potential relevance of their results. Also, the studies of Lee et al 3 Only three studies perform a cost analysis that demonstrates a potentially favourable economic impact of the use of G-CSF after PBSC transplantation. In contrast with the reports of Lee et al and McQuaker et al, our results do not support a clear advantage from the use of filgrastim. In Table 7 Randomized prospective studies using G-CSF after PBSC transplantation contrast, the use of G-CSF in our patients slightly raises the costs of transplantation.
In conclusion, whilst this study is not a placebo-controlled study, our data indicate an absence of a clear clinical benefit from the post-PBSC autotransplantation use of G-CSF in adults, and this accords with another recently published study in children. 5 Nevertheless, we feel a larger study is required to confirm this important question or deny this conclusion.
